Drug intelligence / Profile preview

HRS-7156

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-7156 is an orally bioavailable small molecule mineralocorticoid receptor antagonist (MRA) developed by Shandong Suncadia Medicine, a subsidiary of Jiangsu Hengrui Pharmaceuticals. It is designed to selectively inhibit the mineralocorticoid receptor, thereby blocking the physiological effects of aldosterone, which is a key driver of inflammation, fibrosis, and fluid retention in cardiovascular and renal pathologies. The drug is currently in Phase I clinical development, where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy participants. Potential therapeutic indications for HRS-7156 include hypertension, heart failure, and chronic kidney disease.

Targets

MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on HRS-7156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-7156.

Explore the full profile